Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Area of Science:

• Neuroimmunology
• Virology
• Clinical Neurology

Background:

• Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system.
• Identifying triggers and predictors of MS conversion from clinically isolated syndromes (CIS) is crucial for early intervention.
• Immune responses to viral agents are implicated in MS pathogenesis.

Purpose of the Study:

• To investigate immune responses to candidate viral triggers in CIS patients.
• To assess the predictive value of these immune responses for conversion to MS.
• To correlate viral immune responses with disease markers and progression.

Main Methods:

• A cohort of 147 CIS patients and 50 controls were assessed for immune responses to Epstein-Barr virus (EBV), human herpesvirus 6, cytomegalovirus (HCMV), and measles.
• Humoral and cellular immune responses were measured.
• Patients were followed for a mean of 7 years to track conversion to MS and disease progression.

Main Results:

• CIS patients exhibited significantly increased humoral and cellular immune responses to EBV-nuclear antigen-1 (EBNA1) compared to controls.
• Immune responses to EBNA1 correlated with baseline MRI lesion load and clinical criteria, as well as with lesion development and disability scores during follow-up.
• Higher EBNA1-specific IgG responses predicted conversion to MS in a Cox regression model.

Conclusions:

• Elevated immune responses targeting EBNA1 are a specific finding in CIS patients.
• EBNA1-specific IgG titers show potential as a prognostic biomarker for MS conversion and disability progression.
• These findings highlight the role of EBV in MS pathogenesis and offer a potential tool for risk stratification.